05.28.24 -- Stop Fixating On CDMO Pricing!

Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

This study used Oxford Nanopore Technologies' Direct RNA Sequencing Kit and obtained successful sizing of poly(A) tail regions. The results are presented in a histogram and table format.

To find the plasmid manufacturer with the appropriate knowledge and experience to manufacture your plasmid with quality and efficiency, you’ll need to recognize the offerings of a seasoned supplier.

There are certain roles that must be filled before you move into manufacturing to avoid costly delays and incur non-value-added expenses. Discover what those roles are and get ideas on how to fill them.

Learn about the drug development hurdles that must be overcome to deliver on the promise of mRNA.

Advancements in viral vector design and manufacturing have yielded significant improvements in key areas. Download the e-book to keep abreast of innovations in this dynamic and rapidly evolving space.

Purified adeno-associated viruses (AAVs) are prepared as a variety capsid species that must be characterized and quantified to ensure safety and efficacy.

Finding an experienced partner dedicated to reducing risk of contamination and capable of growing with you as project advances through clinical trial stages is essential.

Treg cell therapy holds promise for patients grappling with debilitating diseases. Review strategies for manipulating Treg activity to unleash the full potential of immunotherapy.

Manufacturers with proven expertise in areas like viral vector production and analytics are needed now more than ever to get deliverable gene editing therapies to patients.

Examine an improved platform process for the creation of engineered plasmids that afford significantly higher titers and productivity levels compared to standard systems.

Learn how we can help you move your pipeline forward, whether you manufacture with us at WuXi Advanced Therapies, in-house, or with one of our fellow CDMOs.

Catalent’s UpTempo℠ AAV platform process is a scalable, cGMP-ready process for viral vector manufacturing that can reduce the current 18- to 20-month development timeline for drug products in half.